Trial Profile

A Phase 2, Multi-Center Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 26 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

03 Nov 2025 According to an Endeavor BioMedicines media release. based on positive results of this trial the European Medicines Agency (EMA) granted PRIority MEdicines (PRIME) designation for taladegib (ENV-101), for the treatment of idiopathic pulmonary fibrosis (IPF).
03 Nov 2025 Results presented in the Endeavor BioMedicines media release.
30 Sep 2025 According to an Endeavor BioMedicines Media Release, company announced that data from this study published at The Lancet Respiratory Medicine.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com